- Home
- EBS vs BCYC Comparison
EBS vs BCYC Comparison
Compare EBS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- BCYC
- Stock Information
- Founded
- EBS 1998
- BCYC 2009
- Country
- EBS United States
- BCYC United Kingdom
- Employees
- EBS N/A
- BCYC N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- BCYC Health Care
- Exchange
- EBS Nasdaq
- BCYC Nasdaq
- Market Cap
- EBS 423.6M
- BCYC 492.1M
- IPO Year
- EBS 2006
- BCYC 2019
- Fundamental
- Price
- EBS $9.11
- BCYC $7.90
- Analyst Decision
- EBS Strong Buy
- BCYC Buy
- Analyst Count
- EBS 2
- BCYC 11
- Target Price
- EBS $13.50
- BCYC $22.91
- AVG Volume (30 Days)
- EBS 969.4K
- BCYC 307.0K
- Earning Date
- EBS 10-29-2025
- BCYC 10-30-2025
- Dividend Yield
- EBS N/A
- BCYC N/A
- EPS Growth
- EBS N/A
- BCYC N/A
- EPS
- EBS 2.53
- BCYC N/A
- Revenue
- EBS $851,600,000.00
- BCYC $19,281,000.00
- Revenue This Year
- EBS N/A
- BCYC N/A
- Revenue Next Year
- EBS $19.24
- BCYC N/A
- P/E Ratio
- EBS $3.63
- BCYC N/A
- Revenue Growth
- EBS N/A
- BCYC N/A
- 52 Week Low
- EBS $4.02
- BCYC $6.10
- 52 Week High
- EBS $12.73
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- EBS 54.66
- BCYC 51.72
- Support Level
- EBS $9.07
- BCYC $7.80
- Resistance Level
- EBS $10.10
- BCYC $9.16
- Average True Range (ATR)
- EBS 0.49
- BCYC 0.45
- MACD
- EBS 0.01
- BCYC 0.02
- Stochastic Oscillator
- EBS 53.00
- BCYC 30.24
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.